Switzerland· 52068010
Mycobutin, Hartkapseln
A rifabutin product containing rifabutinum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rifabutin is registered in 15 of 19 countries.
Countries holding a registration under ATC J04AB04 (rifabutin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Rifabutin · ATC J04AB04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rifabutin costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- Switzerland: $5.51 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Rifabutin · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.51
The record
At a glance
Swissmedic (Switzerland)- Active substance
- rifabutinum
- Manufacturer
- Pfizer AG
- Country
- Switzerland (CH)
- ATC code
- J04AB04
- ATC class
- Rifabutin
- Defined daily dose
- 0.15 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768052068010930 StkCHF 137
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
278 interactions on record for rifabutin.
Graded by severity as the source publishes them — 91 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifabutin · interactions on record
278 records
- 91 severe
- 146 moderate
- 8 minor
Most severe, free to view
- RolapitantA04AD14severe
- EliglustatA16AX10severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
33 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rifabutin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesRifabutinREMEDYREPACK INC.
- FinlandAnsatipinParanova Oy
- NorwayAnsatipinSERB
- United KingdomMycobutin 150mg capsulesPfizer Ltd
- SpainANSATIPIN 150 MG CÁPSULAS DURASBinesa 2002 S.L.
- FranceANSATIPINE 150 mg, géluleSERB
- BelgiumMycobutin 150 mgPfizer
- IrelandMycobutin 150mg Hard CapsulesPfizer Healthcare Ireland Unlimited Company
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Mycobutin
- Belgium · Mycobutin
- Czechia · Mycobutin
- Germany · Mycobutin
- Spain · Ansatipin
- Finland · Ansatipin
- France · Ansatipine
- United Kingdom (Northern Ireland) · Mycobutin, Rifabutin Pfizer
- Ireland · Mycobutin
- Italy · Mycobutin
- Luxembourg · Mycobutin
- Netherlands · Mycobutin
- Portugal · Mycobutin
- Sweden · Ansatipin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6dbb7d41-2cbd-4b81-bdbf-2646275fb776 GET /v1/drugs/6dbb7d41-2cbd-4b81-bdbf-2646275fb776?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "rifabutinum 150 mg",
"valid_from": "1994-03-15",
"limitations": null,
"galenic_form": "Kaps 150 mg",
"therapeutic_area": null,
"sl_inclusion_date": "1994-03-15",
"self_retention_pct": 10
}See everything about rifabutin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.